183 related articles for article (PubMed ID: 31367957)
1. Status quo of osteoporosis treatment in Japan disclosed by the National Database of Health Insurance Claims and Specific Health Checkups: too late in treatment initiation and too few in treated patients?
Kamata Y; Minota S
Arch Osteoporos; 2019 Jul; 14(1):84. PubMed ID: 31367957
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
[TBL] [Abstract][Full Text] [Related]
3. Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.
Starr J; Tay YKD; Shane E
Curr Osteoporos Rep; 2018 Aug; 16(4):519-529. PubMed ID: 29951870
[TBL] [Abstract][Full Text] [Related]
4. Comparison of radiological and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar osteoporotic vertebral fracture.
Jeon S; Yu D; Kim S; Kim SW; Jeon I
Osteoporos Int; 2024 May; 35(5):795-804. PubMed ID: 38261013
[TBL] [Abstract][Full Text] [Related]
5. Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
Tan EH; Robinson DE; Jödicke AM; Mosseveld M; Bødkergaard K; Reyes C; Moayyeri A; Voss A; Marconi E; Lapi F; Reinold J; Verhamme KMC; Pedersen L; Braitmaier M; de Wilde M; Ruiz MF; Aragón M; Bosco-Levy P; Lassalle R; Prieto-Alhambra D; Sanchez-Santos MT
Osteoporos Int; 2023 Oct; 34(10):1771-1781. PubMed ID: 37436441
[TBL] [Abstract][Full Text] [Related]
6. Nocebo-associated treatment discontinuation with subcutaneous anti-osteoporotic drugs. A systematic review and meta-analysis of placebo-arm dropouts in randomized-controlled trials.
Yavropoulou MP; Kasdagli MI; Makras P; Diomatari KM; Anastasilakis AD; Mitsikostas DD; Kassi E; Sfikakis PP; Kravvariti E
Maturitas; 2024 Jan; 179():107874. PubMed ID: 37976923
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study.
Cosman F; Cooper C; Wang Y; Mitlak B; Varughese S; Williams SA
Osteoporos Int; 2022 Aug; 33(8):1703-1714. PubMed ID: 35524068
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary.
Fisher A; Martin J; Srikusalanukul W; Davis M
Clin Interv Aging; 2010 Nov; 5():355-62. PubMed ID: 21228901
[TBL] [Abstract][Full Text] [Related]
9. Global Epidemiology of Hip Fractures: Secular Trends in Incidence Rate, Post-Fracture Treatment, and All-Cause Mortality.
Sing CW; Lin TC; Bartholomew S; Bell JS; Bennett C; Beyene K; Bosco-Levy P; Bradbury BD; Chan AHY; Chandran M; Cooper C; de Ridder M; Doyon CY; Droz-Perroteau C; Ganesan G; Hartikainen S; Ilomaki J; Jeong HE; Kiel DP; Kubota K; Lai EC; Lange JL; Lewiecki EM; Lin J; Liu J; Maskell J; de Abreu MM; O'Kelly J; Ooba N; Pedersen AB; Prats-Uribe A; Prieto-Alhambra D; Qin SX; Shin JY; Sørensen HT; Tan KB; Thomas T; Tolppanen AM; Verhamme KMC; Wang GH; Watcharathanakij S; Wood SJ; Cheung CL; Wong ICK
J Bone Miner Res; 2023 Aug; 38(8):1064-1075. PubMed ID: 37118993
[TBL] [Abstract][Full Text] [Related]
10. A real-world study of treatment patterns among patients with osteoporotic fracture: analysis of a Japanese hospital database.
Hagino H; Yoshinaga Y; Hamaya E; Lin TC; Ajmera M; Meyers J
Arch Osteoporos; 2023 Jan; 18(1):23. PubMed ID: 36683098
[TBL] [Abstract][Full Text] [Related]
11. Antiresorptive Drugs and the Risk of Femoral Shaft Fracture in Men and Women With Osteoporosis: A Cohort Study Using the National Database of Health Insurance Claims of Japan.
Imai T; Hosoi T; Hagino H; Yamamoto T; Kuroda T; Watanabe H; Tanaka S
J Epidemiol; 2023 Dec; 33(12):633-639. PubMed ID: 36567127
[TBL] [Abstract][Full Text] [Related]
12. [Prescription of osteoporosis drugs and secondary fracture prevention still at low levels and with large regional variation].
Modig K; Meyer A; Ek S; Sääf M; Hedström M
Lakartidningen; 2024 Jan; 121():. PubMed ID: 38343318
[TBL] [Abstract][Full Text] [Related]
13. The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug.
de Waure C; Specchia ML; Cadeddu C; Capizzi S; Capri S; Di Pietro ML; Veneziano MA; Gualano MR; Kheiraoui F; La Torre G; Nicolotti N; Sferrazza A; Ricciardi W
Biomed Res Int; 2014; 2014():975927. PubMed ID: 24689066
[TBL] [Abstract][Full Text] [Related]
14. Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in primary care: a qualitative study.
Swart KMA; van Vilsteren M; van Hout W; Draak E; van der Zwaard BC; van der Horst HE; Hugtenburg JG; Elders PJM
BMC Fam Pract; 2018 Aug; 19(1):141. PubMed ID: 30139341
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians.
Qaseem A; Hicks LA; Etxeandia-Ikobaltzeta I; Shamliyan T; Cooney TG; ; Cross JT; Fitterman N; Lin JS; Maroto M; Obley AJ; Tice JA; Tufte JE
Ann Intern Med; 2023 Feb; 176(2):224-238. PubMed ID: 36592456
[TBL] [Abstract][Full Text] [Related]
16. Drug adherence and treatment duration for denosumab and mortality risk among hip fracture patients.
Tsai YL; Wu CH; Li CC; Shih CA; Chang YF; Hwang JS; Tai TW
Osteoporos Int; 2023 Oct; 34(10):1783-1791. PubMed ID: 37466659
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis Medications Prevent Subsequent Fracture in Frail Older Adults.
Chattaris T; Oh G; Gouskova NA; Kim DH; Kiel DP; Berry SD
J Bone Miner Res; 2022 Nov; 37(11):2103-2111. PubMed ID: 36168189
[TBL] [Abstract][Full Text] [Related]
18. Denosumab use reduces risk of rheumatoid arthritis in patients with osteoporosis.
Chen CH; Liao HT; Chen HA; Yen YN; Chen CH
Clin Exp Rheumatol; 2024 May; 42(5):1020-1028. PubMed ID: 38179713
[TBL] [Abstract][Full Text] [Related]
19. Adherence with brand versus generic bisphosphonates among osteoporosis patients: a new-user cohort study in the French National Healthcare Insurance database.
Viprey M; Xue Y; Rousseau A; Payet C; Chapurlat R; Caillet P; Dima A; Schott AM
Sci Rep; 2020 May; 10(1):7446. PubMed ID: 32366863
[TBL] [Abstract][Full Text] [Related]
20. Premenopausal Osteoporosis.
Cohen A
Endocrinol Metab Clin North Am; 2017 Mar; 46(1):117-133. PubMed ID: 28131128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
